The UK’s medicines regulator has proposed a new, unique framework to oversee the safety, quality and effectiveness of innovative medicines that are manufactured at the point of care (POC).
UK Claims World First With ‘Point Of Care’ Manufacturing Rules
MHRA Says New Rules Will Increase Availability Of Innovative New Products
The MHRA says its proposals for a new, tailormade regulatory regime for personalized medicines manufactured at the point of care are evidence of its “intent to move away from a common perception of regulators as a progress blocker to a progress enabler.”
